Skip to content

Kazia Therapeutics Ltd

KZIA Nasdaq SEC CIK 1075880

Follow Kazia Therapeutics Weekly email: filings, results, news

News

5 stories filed under Kazia Therapeutics, grouped into ongoing threads

Paxalisib's

Thread · 3 stories

Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript

Markets 20 d ago

Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data

Markets 24 d ago

Kazia Therapeutics: Upcoming Data May Validate Best-In-Class Potential Of Paxalisib

Markets 28 d ago

More coverage

BTIG raises Kazia Therapeutics stock price target on trial data

Markets 23 d ago

Kazia Therapeutics prices $40 million public offering

Markets 27 d ago 2 sources

Profile

Headquarters: SYDNEY NSW
Sector: Healthcare
Industry: Pharmaceutical Preparations

Peers

Where this page comes from

Profile · SEC EDGAR

News · 5 stories clustered from the RSS aggregator